Biotechnological innovations in the pharmaceutical industry in Poland 2009 provides a comprehensive overview of the biotechnology market in Poland. Covering major industry trends and events, it touches on both domestic and international occurrences that have significance to the Polish market. The report also investigates the size of the market and the most important innovations relevant to the pharmaceutical sector in recent years. From an operational point of view, the report profiles the major players active on the Polish market, as well as the legislative setting they face. A directory of the 20 largest biopharmaceutical companies and developmental forecasts up to 2011 is included.
The report also comprises:
the value of biotechnology market Polish pharmaceutical industry
details on Polish biotech firms investing in development of domestic and international market
data on niche biotech market segments in Poland
key players on the market profiles
undergoing investments in Poland
legislation briefing regarding biotechnology market in Poland
Biotechnological innovations in the pharmaceutical industry in Poland 2009 was prepared using PMR MarketInsight Methodology.
Table of contents:
Report methodology
Executive summary
Overview of the Polish market of pharmaceutical biotechnology
Key events and trends in the biotechnology sector in Poland
Key trends and events in 2007-2009
Events and trends anticipated for 2009-2011
Key characteristics of the Polish market of biotechnology in pharmaceutics
Value of the Polish market of pharmaceutical biotechnology 2003-2011
Biotech firms in Poland
Foreign investment on the Polish pharmaceutical biotechnology market
Number and classification of Polish biotech firms
Overview of the largest biotech firms on the Polish pharmaceutical market
Biotech companies connected with the pharmaceutical industry
Selected biotechnological innovations of the Polish pharmaceutical industry
Stem cell therapy: Celther
siRNA-based innovative biotech drug: Celon Pharna
Modified monoclonal antibody therapy: Mabion
Tissue engineering and regenerative medicine: Euroimplant
Innovative vaccines against skin and kidney cancer: Biocontract
Innovative platform for the development of biotech drugs: Adamed
Innovation at the point of contact between science and industry: Biotechnology and Antibiotics Institute
Biotech innovations leading to the development of new pharmaceutical substances
Advanced molecular diagnostics for clinical trials: Read-Gene
New technologies for the development of biotech drugs: BioCentrum
Innovative screening and comparative research to find bioactive compounds: Proteon Pharmaceuticals
BioIT as support for the development of innovative drugs: Selvita
Factors material to the development of biotechnology in Poland
Human resources
Opinions about biotechnology in medicine
Legislative environment
Key regulations
Act on genetically modified organisms
Patent law
Legislative support for innovation
Quality standards in the Polish biotech sector
Initiatives supporting the development of innovation and technology transfer
Science & technology and industrial parks
General overview
Current tenants from biotechnology in pharmaceutics and related fields in selected technology parks in Poland
Clusters
EU funding for the development of biotechnology innovations
Access to higher risk capital
List of graphs
List of tables
About PMR
Contact PMR
List of graphs and Tables:
List of graphs
Value (PLN m) and y-o-y growth of the Polish market of pharmaceutical biotechnology, 2003-2011 12,
Bioton’s revenues (PLN m) and revenue y-o-y change, 2003-2008
Bioton’s net financial result (PLN m), 2003-2008
Bioton’s revenues and net financial result (PLN m), Q1 2008 and Q1 2009
IBSS Biomed’s revenues (PLN m) and y-o-y revenue change in Poland, 1998-2007
IBSS Biomed’s net profit (PLN m) and net profit y-o-y change in Poland, 1998-2007
Biomed Lublin’s revenues (PLN m) and revenue y-o-y change in Poland, 1998-2008
Biomed Lublin’s net financial result (PLN m) in Poland, 1998-2008
Polfa Tarchomin’s sales value structure, 2007
Polfa Tarchomin’s domestic sales value structure, 2008
Polfa Tarchomin’s revenues (PLN m) and revenue y-o-y change, 1998-Q1 2009
Polfa Tarchomin’s net financial result (PLN m), 1998-Q1 2009
Percentage shareholdings in Mabion of Poland, 2009
Euroimplant’s net financial result (PLN’000) in Poland, 2007-2008
Biocontract’s financial results (PLN m) in Poland, 2007
Adamed’s revenues (PLN m) and revenue y-o-y change in Poland, 1999-2008
Adamed’s net financial result (PLN m), 1999-2008
Read-Gene’s net financial result (PLN’000) in Poland, 2005-2009
Forecast for Read-Gene’s revenue and net profit structure in Poland, 2009
BioCentrum’s revenues (PLN m) and revenue y-o-y change in Poland, 2004-2007
BioCentrum’s net profit (PLN’000) and net profit y-o-y change in Poland, 2004-2007
Number of candidates to biotechnology and biomedical engineering specialisation in Poland, 2006-2008
Projected demand for graduates of natural science specialisations in next 5 and 15 years (number of selections of Voivod Labour Offices) in Poland, December 2008
Assessment of results of use of modern biotechnological methods in Poland
Poles’ opinion on use of biotechnology to produce new drugs and vaccines
Opinions on the statement “research into drugs and vaccines to be used in biotechnology and genetic engineering comprise a threat to the environment or human life”
Applications for closed use of GMOs in projects with applications in medicine and pharmaceutics in Poland, 2002-H1 2009
Number of applications for closed GMO use by biotech firms of the pharmaceutical industry in Poland, 2002-H1 2009
List of tables
Structure of Bioton Capital Group, 2008
The most important science and technology parks which have as a priority direction the support of the development of biotechnological companies in Poland, 2009
Selected biotechnology-related cluster initiatives relevant to the pharmaceutical and related industries in Poland, 2009
Companies and institutions from the biopharmaceutical and related sectors, which have received financing from the Innovative Economy Operational Programme and project value in Poland, 2009
Polish version also available!
